Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

6

Revenue 2017

Johnson & Johnson

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Johnson & Johnson's 2013 sales performance.

Johnson & Johnson

BMS to test Vedanta’s bacterial therapy with Opdivo

BMS to test Vedanta’s bacterial therapy with Opdivo

In November, a three-year collaboration with Johnson &Johnson (J&J) resulted in its first clinical trial, and a $12m milestone payment for Vedanta.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close Back in the realm of ‘conventional’ CAR-T, China’s Legend Biotech posted encouraging data from a phase 1/2 trial of its Johnson &Johnson (J&J) partnered anti-BCMA therapy

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Dutch biotech Argenx claims $1.8bn licensing deal with J&J Deal centres around blood cancer candidate cusatuzumab. Argenx of the Netherlands has licensed a drug for blood cancers to Johnson &Johnson in a deal that gives it a hefty $300m upfront

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma busy field at first glance, although it remains to be seen whether it will challenge other emerging therapies, and particularly CAR-T candidates from Bluebird Bio, Celgene/Juno and Johnson ... treated in trials of Bluebird’s CAR-Ts had seven or more,

ASH18: CAR-T and drugs give new options for multiple myeloma

ASH18: CAR-T and drugs give new options for multiple myeloma Later today, Johnson &Johnson will present new  phase 1 data on its early-stage anti-BCMA CAR-T LCAR-B38M in relapsed myeloma, after revealing a 100% response rate at an

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics